Structure Therapeutics Appoints Ted W. Love, M.D., to Board of Directors
SAN FRANCISCO, Aug. 03, 2023 (GLOBE NEWSWIRE) — Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage…
News
Terns Pharmaceuticals Announces Leadership Transition
Senthil Sundaram Stepping Down as Chief Executive Officer for Health Reasons FOSTER CITY, Calif., Aug….
Terns Pharmaceuticals Announces Leadership Transition
Senthil Sundaram Stepping Down as Chief Executive Officer for Health Reasons FOSTER CITY, Calif., Aug….
Telesis Bio to Report Second Quarter Financial Results on Thursday, August 10, 2023
SAN DIEGO, Aug. 03, 2023 (GLOBE NEWSWIRE) — Telesis Bio (Nasdaq: TBIO), a leader in automated…
Telesis Bio to Report Second Quarter Financial Results on Thursday, August 10, 2023
SAN DIEGO, Aug. 03, 2023 (GLOBE NEWSWIRE) — Telesis Bio (Nasdaq: TBIO), a leader in automated…
Oncternal Therapeutics to Provide Business Update and Report Second Quarter 2023 Financial Results
SAN DIEGO, Aug. 03, 2023 (GLOBE NEWSWIRE) — Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage…
Oncternal Therapeutics to Provide Business Update and Report Second Quarter 2023 Financial Results
SAN DIEGO, Aug. 03, 2023 (GLOBE NEWSWIRE) — Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage…
Cellectis Provides Business Updates and Preliminary Financial Results for Second Quarter 2023
Updated clinical & translational data on BALLI-01 trial (evaluating UCART22 in r/r B-cell ALL) presented at…
Cellectis Provides Business Updates and Preliminary Financial Results for Second Quarter 2023
Updated clinical & translational data on BALLI-01 trial (evaluating UCART22 in r/r B-cell ALL) presented at…
Praxis Precision Medicines to Participate at the 2023 Wedbush PacGrow Healthcare Conference
BOSTON, Aug. 03, 2023 (GLOBE NEWSWIRE) — Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage…
Praxis Precision Medicines to Participate at the 2023 Wedbush PacGrow Healthcare Conference
BOSTON, Aug. 03, 2023 (GLOBE NEWSWIRE) — Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage…
IGM Biosciences Announces Second Quarter 2023 Financial Results
– Continued progress in clinical development across portfolio –– Public equity offering and concurrent private…
IGM Biosciences Announces Second Quarter 2023 Financial Results
– Continued progress in clinical development across portfolio –– Public equity offering and concurrent private…
Cidara Therapeutics Provides Corporate Update and Reports Second Quarter 2023 Financial Results
SAN DIEGO, Aug. 03, 2023 (GLOBE NEWSWIRE) — Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology…
Cidara Therapeutics Provides Corporate Update and Reports Second Quarter 2023 Financial Results
SAN DIEGO, Aug. 03, 2023 (GLOBE NEWSWIRE) — Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology…
Vir Biotechnology Provides Corporate Update and Reports Second Quarter 2023 Financial Results
– Phase 2 data readouts from ongoing chronic hepatitis B and chronic hepatitis delta programs…
Revolution Medicines to Report Financial Results for Second Quarter 2023 After Market Close on August 8, 2023
REDWOOD CITY, Calif., Aug. 03, 2023 (GLOBE NEWSWIRE) — Revolution Medicines, Inc. (Nasdaq: RVMD), a…
Sana Biotechnology Reports Second Quarter 2023 Financial Results and Business Updates
Enrolling patients in ARDENT, the SC291 Phase 1 clinical trial in B-cell malignancies, with initial…
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Party City Holdco Inc. (PRTY, PRTYQ) on Behalf of Investors
LOS ANGELES–(BUSINESS WIRE)–Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm,…
Myriad Genetics Reports Second Quarter 2023 Financial Results and Reaffirms 2023 Revenue and Adjusted EPS Guidance; Generates the Fourth Consecutive Quarter of Double-Digit Year-Over-Year Testing Volume Growth
Highlights: Second quarter testing volume grew 17% year-over-year, excluding contributions from the SneakPeek® Early Gender…